Clinical study for effectiveness of rituximab for acquired coagulopathy
Phase 2
- Conditions
- acquired coagulopathy
- Registration Number
- JPRN-UMIN000024612
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
(1) The men that an agreement is not obtained in preventing conception during study drug dosing period. (2) The women who may be pregnant during nursing during pregnancy and the women who hope for pregnancy during study drug dosing period. (3) The patients who are proved to have an HIV antibody. (4) The patients that positive was confirmed in one or more with HBs antigen, HBs antibody, anti-hepatitis B core antigen and HCV antibody. (however, we do not do it with the subject of the exclusion by this rule when a thing with the vaccination is clear when an examination of hepatitis B is positive) (5) In addition, the patients whom doctor attending judged to be inadequate as an object of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disappearance of coagulation factor inhibitor on day 56 after rituximab administration
- Secondary Outcome Measures
Name Time Method